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S328 Poster Session IIchemotherapy for that shift, between the charge nurse and the pa-
tient’s assigned nurse was completed at shift’s beginning. Debrief-
ing between the charge nurse and the patient’s assigned nurse was
completed at shift’s end and consisted of recording the nurse’s re-
sponse to the question, ‘‘Did you have 2 RNs check chemo in the
room?’’
Of the 90 opportunities for chemotherapy administration, all che-
motherapy doses were double-checked at the bedside 100% of the
time after the bedside check implementation. Medication variance
data revealed no patient misidentification chemotherapy errors
were reported for the 3 months prior to and after implementation.
BMT nursing staff consistently changed their practice by imple-
menting a bedside check of chemotherapy. Medication variance
data was inconclusive, as no errors related to patient misidentifica-
tion involving chemotherapy were reported prior to or after the
practice change.
As this practice change continues, we anticipate 0% incidence of
patient misidentification chemotherapy administration-related
errors. This bedside check may offer more opportunities for patients
to inquire about their chemotherapy. Patient satisfaction may
improve if patients see extra care taken to ensure they receive the
intended therapy.469
TWICE DAILY INTRAVENOUS TACROLIMUS (FK-506) IS A SAFE AND
EFFECTIVE GRAFT VS. HOST DISEASE (GVHD) PROPHYLAXIS FOR PEDI-
ATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL (HSCT) RECIPIENTS
Skeens, M.A., Pai, V., Garee, A., Bajwa, R., Gross, T., Termuhlen, A.,
Soni, S. Nationwide Children’s Hospital, Columbus, OH; The Ohio State
University, Columbus, OH; The Ohio State University, Columbus, OH
Background: Tacrolimus (FK-506) is highly effective in prevent-
ing GVHD in allogeneic HSCT recipients. Traditionally, tacroli-
mus is administered as a 24-hour continuous infusion. This
schedule is logistically difficult. We report our pediatric experi-
ence with twice-daily bolus administration of intravenous (IV)
FK-506.
Methods: From March 2006 until July 2009, 25 pediatric patients
undergoing allogeneic HSCT have received twice daily bolus infu-
sions of iv FK-506 for GVHD prophylaxis. FK-506 was started at
an initial dose of 0.015 mg/kg IV bolus administered as a two hour
infusion beginning on Day -2 or -3 and then given every twelve
hours. Trough drug levels were drawn before the fifth dose and
then monitored twice weekly. The dose was adjusted to maintain
a trough drug level range between 5-15 ng/ml. Bolus iv FK-506 in-
fusions were continued till patients were ready to be transitioned to
the oral route.
Results: Median age of recipients was 10 years (14months –17
years). 16/25 (64%) of patients received matched unrelated grafts
and 9/25 (36%) received matched related donor HSCT Stem cell
sources included bone marrow, peripheral blood and cord blood.
Majority of the patients had also received short course methotrex-
ate or mycophenolate mofetil in combination with iv FK-506 for
GVHD prophylaxis. 10/25 patients had also received anti-thymo-
cyte globulin (ATG).
All bolus infusions of iv-FK-506 were well tolerated, Nephrotox-
icty (defined as 2x baseline creatinine at any time-point during FK-
506 adminitration) was detected in 11/25 (44%) patients. Most of
these patients were receieving other nephrotoxic agents also. Past
studies of continuous infusion FK-506 report nephrotoxicity rates
of 60-80% using the same criteria. No patient required dialysis.
No patient developed HUS/TTP. 12% of patients developed hyper-
tension requiring medical intervention. One patient developed
PRES with seizures and tremors.
Only 1/25 patients developed Grade II GVHD. No Grade III-IV
GVHD was identified.
This was effective GVHD control when compared to historical
results of continous iv FK-506.
Conclusions: Intermittent bolus infusions of FK-506 are easy to ad-
minister and do not correlate with any increased toxicity or risk of
GVHD when compared to past reports of continuos iv administra-
tion.Since access to central venous lines is an important issue inchildren, further studies are warranted to confirm the safety and ef-
ficacy of intermittent Tacrolimus administration.470
BRIDGING THE UNMET NEEDS OF YOUNG ADULTS: CREATING A
SUPPORT GROUP FOR YOUNG ADULT PATIENTS ON THE STEM CELL
TRANSPLANT SERVICE
Rimkus, C., Chiang, K. Barnes-Jewish Hospital, St. Louis, MO
Young adults, ages 18-35, have unique psychosocial needs that
differ from their older counterparts with the same cancer. The
transplant service at a large comprehensive cancer center includes
patients who have all blood related cancers that are being treated
with or without a stem cell transplant. The transplant team appre-
ciates the unique needs of the young adult. Several attempts
aimed at addressing these needs have failed. Our psychosocial ser-
vice developed an outpatient young adult support group that
failed due to poor attendance. Individual support has not been
easily accepted. We even attempted to engage the young adults
in an interactive game/book/DVD program, with minimal success.
Over the past year, the inpatient staff started noticing the young
adult patients gathering in common spaces, even going to each
other rooms to gain the support from other patients with like dis-
eases and concerns. Given that the average length of stay for the
blood cancer patient is three weeks and that the young adults have
been interactive in the already established discharge planning
class, the staff felt that an inpatient support group was a viable
untapped option. The staff asked the young adults if they felt
a young adult support group that was held on the unit would
be helpful to them. The twenty-five to thirty-five year olds were
very interested in having their needs addressed and were inter-
ested in gaining the support of others with like concerns. The pa-
tients younger than twenty-five were non-committal. Partnering
with the psycho-oncology service, the clinical nurse specialist de-
veloped a young adult support group. A proposal was developed
and presented to the cancer center’s patient programming com-
mittee as well as the director of oncology services. Once accepted,
the proposal was presented to the nursing staff. Group ground
rules have been established to address the potential anger and
emotion that can be evoked from this population. Marketing for
the program will include having the unit staff and chaplain pro-
mote attendance. The goal of this poster is to outline the steps
included in developing a support group, identifying the challenges
as well as rewards. The plan is to start this inpatient young adult
support group in November and collect data for 3 months as to
attendance, feedback from patients and then eventually to see if
this leads to opportunities to help this psychologically under-
served population.471
CHEMOTHERAPY DOSE ADJUSTMENT FOR OBESITY IN HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Jakubowski, R.M.1, Isola, L.2, Cunningham, R.1, Kim, S.3 1 Nursing;
2 Medicine; 3 Mount Sinai Medical Center, New York, NY
More than 50 million adults in the US are overweight and al-
most 70% qualify for the diagnosis of obesity. In 2010, 1.6 million
new cases of cancer are expected to be diagnosed. That number is
expected to increase by 45% in the next 20 years. Recent studies
have shown that obesity is associated with an increased risk of cer-
tain types of cancer. A large number of patients with cancer will
receive chemotherapy as treatment for their disease. Although re-
nal, cardiac and liver function play a role in dose adjustment of
chemotherapy, patient and drug specific factors (i.e. obesity,
drug’s protein binding, its lipophilicity) must also be considered.
The level of excess body weight that requires dose adjustment re-
mains controversial. Myeloablative hematopoietic stem cell trans-
plantation (HSCT) is based on the use of high doses of
chemotherapy such as busulfan. High serum concentrations of
such drugs have been associated with the development of life-
threatening complications like veno-occlusive disease. For this
reason, many practitioners empirically adjust chemotherapy dosing
in obese patients by using adjusted weight or capping body surface
MLP-Physician Perceptions
MLP* Physician*
Appt Autonomy 82.3 86.4
Appt Practice Scope 94.1 86.9
Effective Communication with Physician 82.4 90
Fairly Compensated 64.7 57.1
Mechanism for Prof Development 58.8 61.1
Appt Amount of Supervision 97.1 85
Appt Amount of Feedback 73.5 76.2
Tolerable Workload 61.8 80.9
Tolerable Emotional Demands 76.5 95.5
* Percentage Who Agree.
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lapse is unknown. We sought to establish a standard of practice
for dose adjusting chemotherapy in obese patients at our center
which would maximize treatment without excessive toxicity or
underdosing. A survey of practices of dose adjustment by pharma-
cists at 10 transplant centers was undertaken, as well as a review of
more than 25 publications related to transplantation/obesity/and
dose adjustment of chemotherapy. Four centers adjusted all drugs
using the formula of ideal body weight (IBW) + [(actual body
weight – IBW) x 25 or 40%]. Four centers used the same 25 or
40% adjustment only for obese patients (.20-30% IBW). One
center used actual weight or IBW, whichever was less, without
other adjustment. The last center used IBW + 10% of IBW for
dosing, if the difference between actual and IBW was .50 lbs.
None of these institutions addressed the individual drugs physio-
chemical properties such as liphophilicity. The literature review
revealed no consensus beyond the practice of dose adjusting for
actual body weight $120% IBW. With the increasing number
of overweight patients undergoing HSCT, and the limited phar-
macokinetic data available on high dose chemotherapy in over-
weight patients, studies are needed to establish a standard
approach.Figure 1: Implementation of Plerixafor in Planned G-CSF Priming
for First Attempt at Stem Cell Mobilization and Harvesting
Begin GCSF (4 day prime) Check pCD34, Day 4,
continue GCSF
Goal of Colleciton Single Transplant Multiple Transplants
pCD34. 10 pCD34. 20
Apheresis Yield .1.5 x 10(6)
CD341 cells/kg
If Yes Collect to Goal
or yield\0.5 x 10(6)
CD341 cells/kg x2 days
If No and not receiving Plerixafor Add Plerixafor QPM, apheresis next AM
Discuss results with MD
This is to be a figure of an algorithm and does not fit into table form.472
MID-LEVEL PRACTITIONER-PHYSICIAN COLLABORATION IN PEDIATRIC
HSCT PROGRAMS
Fisher, V.L.1, Barnes, Y.2, Olson, E.A.3, Skeens, M.A.4, Nieder, M.L.5
1 Pediatric Blood and Marrow Transplant Consortium, Arcadia, CA;
2 St. Louis Children’s Hospital, St. Louis, MO; 3 Aflac Cancer Center, At-
lanta, GA; 4 Nationwide Children’s Hospital, Columbus, OH; 5 All Child-
ren’s Hospital-Moffitt Cancer Center, St. Petersburg, FL
Mid-level practitioners (MLP’s) are utilized in the inpatient and
ambulatory care settings in many pediatric HSCT programs.
While strict guidelines exist surrounding the training of resident
physicians and fellows, practice guidelines for MLP’s are less well
defined and vary by state or provincial regulations. In an effort to
enhance the MLP-Physician collaborative relationship, we de-
signed a brief survey to determine how MLP’s and physicians per-
ceive the MLP-Physician relationship. On-line surveys were sent to
75 Pediatric Blood and Marrow Transplant Consortium centers.
Physicians and MLP’s received nearly identical surveys; only the
syntax was altered to reflect that the response was MLP opinion
or physician perception. Thirty-six MLP’s and 25 physicians par-
ticipated in the survey.
The survey asked the MLP’s and physicians to define the MLP
clinical role. Results showed that physicians had an excellent under-
standing of this. The physicians acknowledged that the MLP’s play
a role in resident/fellow and nursing education.
Table 1 shows that there was significant agreement between
MLP’s and physicians with respect to autonomy, scope of practice,
communication, and feedback. Both MLP’s and physicians felt that
MLP’s were not compensated fairly. Physicians seem to underesti-
mate the MLP workload and do not fully appreciate the physical
and emotional demands of the MLP role.
There were also misperceptions about how MLP’s spent their
time. For instance, only 28.6% had protected office time, yet 56%
of physicians thought their MLP’s did have this. A majority of phy-
sicians (60%) stated that they had formal sessions with their MLP to
discuss clinical situations and conduct chart reviews/audits. How-
ever, only 38.2% of MLP’s reported that this actually occurred.
Most physicians stated that MLP’s should attend conferences and
encourage the MLP’s to publish. MLP’s concurred with this assess-
ment.
This initial survey suggests that MLP’s and physicians have
a strong collaborative relationship. There responses show that
physicians and MLP’s need to develop strategies for regular struc-
tured feedback. If publishing manuscripts, conducting research or
taking leadership roles in teaching are desired, than more
protected time needs to be provided to the MLP. Physicians
should also recognize that there is a significant physical and emo-
tional aspect to the MLP role. This survey will provide a founda-
tion for future research into optimizing the MLP-Physician
collaboration.473
ALGORITHM FOR NURSING IMPLEMENTATION OF A RISK ADAPTED AP-
PROACH (RAA) TO STEM CELL MOBILIZATION UTILIZING MOZOBIL
(PLERIXAFOR)
Miceli, T.S., Goodew, R.A., Gronseth, M.J., Kaiser, L.L.,
Knudsvig, M.M., Theuer, J.M. Mayo Clinic, Rochester, MN
Autologous stem cell (SC) transplant is an accepted treatment mo-
dality for non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma
(MM). One eligibility requirement to proceed to high dose chemo-
therapy with (SC) rescue is securing adequate SCs (2.0  10(6)
CD34+ cells/kg weight) prior to ablative therapy. Ability to mobilize
SCs is unpredictable. For the pt unable to mobilize SCs with GCSF
alone, treatment options become limited. Plerixafor, recently FDA
approved CXCR4 inhibitor, in combination with GCSF, is proven
to more effectively mobilize SCs than GCSF alone, allowing pts to
receive HD chemotherapy and SC rescue.
The high cost of Plerixafor resulted in the Mayo Clinic – Roches-
ter BMT program implementing a RAA of the medication rather
than upfront use.
Pts were separated into two groups. Pts who previously failed (PF)
to mobilize SCs received upfront use of Plerixafor in combination
with GCSF. GCSF began the morning of Day 1. Plerixafor was in-
troduced the evening of Day 4. SC harvesting began the morning of
Day 5. Collections continued until the pt reached target goal, or, col-
lections were discontinued if two consecutive harvest yields were
\0.5  10(6) CD34+ cells/kg weight.
First time mobilizer criteria for initiating Plerixafor was based on
Day 5 peripheral blood CD34+ (pCD34) evaluation and collection
results. If pCD34 was inadequate on Day 5, Plerixafor was started
that evening and collection Day 6. If harvesting yield was\0.5 or
dropped to\0.5  10(6) CD34+, Plerixafor was instituted. Evalu-
ation of the RAA after 6 months resulted in updates to the ap-
proach. If pCD34 was inadequate on Day 4, Day 1 harvesting
yield \1.5 or yield dropped to \0.5  10(6) CD34+, Plerixafor
was added.
Algorithms were created and revised by nurses, approved by phy-
sicians, for nursing implementation of this RAA (Figure 1), which
continue to guide order creation and pt education.
